T. Likhacheva

Standard and increased canakinumab dosing to quiet macrophage activation syndrome in children with systemic juvenile idiopathic arthritis

V. Chasnyk, R. Cron, E. Suspitsin, 2022, Frontiers in Pediatrics.

Proceedings of the 23rd Paediatric Rheumatology European Society Congress: part one

J. Stinson, J. Jaremko, A. Goris, 2017, Pediatric Rheumatology.

The Safety and Efficacy of Tofacitinib in 24 Cases of Pediatric Rheumatic Diseases: Single Centre Experience

O. Kalashnikova, V. Chasnyk, I. Aksentijevich, 2022, Frontiers in Pediatrics.

Identification of the best cutoff points and clinical signs specific for early recognition of macrophage activation syndrome in active systemic juvenile idiopathic arthritis.

O. Kalashnikova, V. Chasnyk, E. Kuchinskaya, 2015, Seminars in arthritis and rheumatism.

FRI0551 Successful Treatment with TOCILIZUMAB Every 4 Weeks Distinguishes Low Disease Activity Group and Possibility to Achieve Drug-Free Remission in Patients with Systemic-Onset Juvenile Idiopathic Arthritis

O. Kalashnikova, V. Chasnyk, E. Kuchinskaya, 2014 .

NLRP12-associated periodic syndrome: A description of the authors' own observation and an analysis of literature data

Margarita Dubko, E. N. Suspitsyn, Anna P. Sokolenko, 2017 .